Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.79, read 2026-10-28
Ethical does not pass the values gate
Price4.58 USD
Fair value4.28
Ethical score70.0/100
Our investment reviews on this name
2026-10-28Read Accumulation4.73-3.2% to today Markdown gives way to Accumulation
2026-10-25Read Markdown4.73-3.2% to today ✓Accumulation gives way to Markdown first Markdown read since October
2026-10-18Read Accumulation4.68-2.1% to today Markdown gives way to Accumulation
2026-10-11Read Markdown4.60-0.4% to today ✓Accumulation gives way to Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Clover Health Investments, Corp. holds its Accumulation at $4.58. Consolidating, no directional conviction, held for 1 days.
As held on the ledger · 2026-10-29
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 1 days
Price at the screen
$4.58
Valuation
N/A trailing · 31.53 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.46
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
34.58%
Below 33%
Interest-bearing cash and securities are 34.6% of assets, above the one-third limit.
Fail
Receivables
43.81%
Below 49%
Money owed to the company is 43.8% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Clover Health Investments,'s business is fine, but its cash and interest-bearing securities are about 35% of its assets, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CLOV's ethical verdict changes
Today CLOV does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-29 screen. The gold marker is the market price at the same screen. The price runs 6.7% above the base estimate.
Third-party analyst targets: 4 covering, consensus None. The average target sits +15% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-29 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Medicare app growth story priced for perfection
Picture a retiree in Florida signing up for a Medicare plan that promises an AI assistant to manage their care. Clover Health is chasing exactly that market with rapid expansion. Revenue is up 62 percent, yet the business still posts a negative 3 percent profit margin and a negative 17 percent return on equity, so the growth has not yet produced real earnings.
At a forward price to earnings ratio of 46 times and a share price well above our assessed fair value, the market is paying for a future that remains unproven. The opportunity rating sits at none because the numbers show a company that is scaling but not yet converting that scale into sustainable profit.
Valuation leaves little margin for the execution risk that comes with turning a loss-making Medicare book profitable while competing against larger insurers. Currency and regulatory shifts in healthcare add further uncertainty that the current price does not appear to discount. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CLOV trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Accumulation$4.60-2.7%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 45% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it none, with a mean price target of $3. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 45% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it none, with a mean price target of $3. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown · changed$4.73+1.1%Entry 9
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 51% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it none, with a mean price target of $3. Insiders have been net sellers over the past quarter.
2026-10-18Accumulation · changed$4.68+1.7%Entry 8
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it none, with a mean price target of $3. Insiders have been net sellers over the past quarter.
2026-10-11Markdown · changed$4.60+1.3%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it none, with a mean price target of $3. Insiders have been net sellers over the past quarter.
2026-10-02Accumulation · changed$4.54+0.0%Entry 6
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it none, with a mean price target of $3. Insiders have been net sellers over the past quarter.
2026-08-25Distribution · changed$4.54-1.7%Entry 5
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it none, with a mean price target of $3.
2026-07-25Markup · changed$4.62-2.3%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it none, with a mean price target of $3.
2026-07-18Accumulation$4.73+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (3 analysts) rates it none, with a mean price target of $3.
2026-07-03Accumulation$4.73+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
